Radiopharmaceuticals Are Having a Breakout Year. What's Next?
The radiopharmaceutical industry has gone from one of oncology's most promising modalities to one of its most heavily invested.
In the past 12 months alone, we've seen positive Phase III data from Novartis, major advancements in alpha therapies from ARTBIO and Orano Med, novel targeting approaches from Molecular Partners, and one of the biggest deals in radiopharmaceutical history with Curium's planned acquisition of Lantheus.
At the same time, developers are racing to secure isotope supply, expand global clinical programmes, and position themselves for the next wave of investment.
The message is clear: radiopharmaceuticals are no longer an emerging field. They're becoming a central pillar of precision oncology.
The Industry's Biggest Questions Haven't Been Answered Yet
Despite the momentum, several critical challenges remain:
Alpha vs Beta: Which Will Win?
With growing excitement around Ac-225 and Pb-212, alpha therapies are attracting significant investment. But established beta emitters such as Lu-177 continue to generate compelling clinical and commercial success.
As pipelines mature, developers are increasingly asking: which isotope class will define the next generation of radioligand therapies?
Can Supply Keep Up With Demand?
Clinical progress means little without access to isotopes.
Recent supply agreements and infrastructure investments have highlighted just how important manufacturing capacity, isotope availability, and supply chain resilience have become for long-term success.
How Do We Scale Globally?
As companies look beyond Europe and North America, expanding trials into Asia presents major opportunities, alongside new regulatory, operational, and logistical challenges.
Why Is Big Pharma Investing So Aggressively?
From acquisitions to strategic partnerships, radiopharmaceuticals are attracting unprecedented attention from pharma leaders and investors.
Where the Industry Will Tackle These Challenges
These questions sit at the heart of the 8th Targeted Radiopharmaceuticals Summit Europe, taking place this December in London.
Designed around the trends shaping the market today, the event features three dedicated tracks:
Discovery & Preclinical
Advancing next-generation targets, novel targeting platforms, and translational science.
Translational & Clinical
Showcasing first-in-human data, dosimetry innovation, clinical development strategies, and regulatory insights.
CMC & Supply
Addressing isotope production, manufacturing scale-up, and supply chain readiness.
Attendees will also dive deeper into some of the industry's hottest discussions, including:
- The Alpha vs Beta isotope debate
- Big Pharma's radiopharmaceutical investment strategy
- Expanding clinical trials into Asia
- Isotope supply and manufacturing challenges
- Phase II-III clinical data and commercial readiness
Learn From the Companies Shaping the Future of RLT
The speaker faculty includes experts from Novartis, AstraZeneca, Johnson & Johnson, Regeneron, Bayer, Curium, MHRA, ARTBIO, Orano Med, Bicycle Therapeutics, Molecular Partners and many more.
As the industry moves from breakthrough science to commercial reality, the organisations that solve today's challenges will define tomorrow's standard of care.
This December, more than 180 radiopharmaceutical leaders will come together in London to discuss what comes next.
Explore the Agenda
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Partner With Us
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Join Europe's TRP Leaders:
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.